INTRODUCTION
Major depressive disorder (MDD) is a common debilitating mental health problem worldwide. It is estimated to be the second main cause of overall disease burden in 2020. [1, 2] The disorder is more prevalent among older adults. The overall prevalence of MDD in geriatric population is estimated to be 10-20% in diff erent cultural populations according to the report of World Health Organization and as many as 10% of adults aged 65 years or more who are seen in primary care se ing have clinically signifi cant depression. [3] Late life depression is considered as a major health problem in many developed countries due to the higher proportion of elderly population. Though the population of Iran comprises largely of young people, but according to the estimation of WHO, the elder population in Iran the diagnosis and treatment of depression in elderly patients. Some studies reports that late life depression may be associated with subsequent mild cognitive impairment and dementia but it is not clear whether depression represents a risk factor for or occurs in the prodromal stage of dementia. [11] Be er understanding of the pathophysiology of the disease would help us in its proper management. Evidence suggests that glutamate has a crucial role in the pathophysiology of mood disorders including depression. [12] Recent studies reported antidepressant response of glutamate neurotransmission modulation. Some studies reported higher level of glutamate in serum and CSF of patients with depression. [13] Others showed that there is a signifi cant relationship between severity of the disease and the glutamate level. [12] N-methyl-D-aspartate (NMDA) is one of the postsynaptic ionotropic receptors that could modulate glutamate neurotransmission via its postsynaptic action. The antidepressant eff ect of NMDA antagonists have been reported in many animal models. [14, 15] In clinical trials a single dose of NMDA receptor antagonist Ketamine has shown a rapid antidepressant eff ect in patients with treatment resistant depression and bipolar depression. [16] Memantine is a low to moderate-affi nity noncompetitive NMDA receptor antagonist. It is approved for the treatment of Alzheimer's disease and recent studies have investigated its utility in the treatment of other psychiatric disorders. Antidepressant activity of memantine is indicated in many animal models but the results of its eff ectiveness on humans are controversial. [15] [16] [17] [18] [19] [20] According to recent preclinical and clinical evidences, it is suggested that add-on memantine could have mood-stabilizing eff ects. Administration of memantine is more favorable than other NMDA antagonists since it does not have psychotomimetic eff ects at therapeutic doses and has fewer side eff ects. [21] Moreover, NMDA antagonists could mediate delayed onset of action of traditional antidepressant agents. [22] Since the elderly o en use many drugs, the use of a drug with minimal side eff ects and drug interactions seems reasonable. In addition, proper management of depression in elderly population would improve the outcome of the disease and reduce its related disability and mortality.
The aim of current research was to investigate the eff ect of addon memantine therapy in elderly patients with depression, who had received citalopram antidepressant in Isfahan.
MATERIALS AND METHODS
In this double-blind, placebo-controlled trial study elderly patients diagnosed recently with depression aged >60 years and who had met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-text revision (DSM-IV-TR) criteria for major depression [8] and a ended the geriatric clinics of Nour hospitals in Isfahan from December 2011 to October 2012, were enrolled. The patients selected by consecutive sampling method. The Medical Ethics Commi ee of the Isfahan University of Medical Sciences approved the study protocol (Research Project Number; 390231), and all subjects gave their wri en consent.
Inclusion criteria were; Depressive elderly patients (aged >60) selected by an interview based on DSM-IV-TR by a resident of psychiatry and were rated by the same psychiatric at fi rst with three scales: Hamilton Depression Rating Scale (HDRS) >17, Geriatric Depression Scale (GDS-15) >5 and Mini Mental State Examination (MMSE) >24.
Exclusion criteria were: Patients with a history of previous psychiatric disorders such as bipolar disorder, psychosis, dementia or substance dependence (during last 6 months), previous severe and unstable medical disorders and history of taking other psychotropic medication.
Selected patients were randomized into two groups: Intervention and placebo groups using permuted block design sampling with size of two for each block. Two consecutive patients were randomly allocated to the treatment and control groups in each step till to complete the sample size.
Sample size was calculated as sixty patients (30 in each group). It was calculated base on confi dence coeffi cient of 95% (1/96) and criterion deviations of Hamilton score (S = 16/7) and the sampling bias (d = 8/5).
The intervention was memantine or placebo (with the same shape and taste as memantine) for 8 weeks. Memantine is administrated in the intervention group with a 5 mg/daily dose for fi rst week, second week dosage of 5 mg twice daily, third week 5 mg in the morning and 10 mg in the evening, forth week 10 mg twice daily and the target dose of 20 mg/ daily continued till eighth week.
All patients received citalopram 10 mg/daily initiation dose for fi rst week and continued with 20 mg/daily for the rest of the study. The 8-week follow-up started since the beginning of administrating the memantine + citalopram or placebo + citalopram in intervention and placebo groups, respectively. All the tablets of memantin and citalopram were manufactured in Sobhan factory in Iran. Baseline characteristics of patients including severity of depression and quality of life were evaluated using GDS-1 HRSD and WHO-QOL-(brief), respectively. Mentioned scores were re-evaluated by the resident of psychiatry during study, at week 4 and 8 a er initiating trial. Results in the intervention and placebo groups were compared in baseline and during the follow-up period.
name of A and B. A questionnaire was fi lled secretly and every patient received a code for trial.
Psychological tests Hamilton depression rating scale (HDRS)
It is a multidimensional clinical assessment scale, which is used to determine the severity of depression based on mood, cognitive and physical symptoms of depression. It is a semistructured interview questionnaire. It has 24 items with (0-4) or three (0-2) Likert spectrum scale and a cut-off point of 17. The validity and reliability of the score was confi rmed in Iran and the Persian version of the scale was used in our study. [23] Geriatric depression scale (GDS-15) It is a 15 item self-report assessment, which was developed from the GDS-30. It is commonly used for screening depression among geriatric population. It consist of 15 yes/no question. Score >5 is suggestive of depression (GDS5-8 mild, GDS 9-11 moderate and GDS12-15 severe depression). In this study, we used the standardized Iranian version of the questionnaire. [24] 
WHO-QOL-(brief)
The WHOQOL-BREF is a 26-item questionnaire for evaluating four domains including psychological, physical, environmental health and social relationships and two QOL and general health items. Scoring rate is ranging from 0-20 for each domain. In this study, we used the standardized Iranian version of the questionnaire. [25] Mini mental state examination (MMSE) MMSE is a 30-item questionnaire for screening and estimation of cognitive impairment as well as follows the course of cognitive changes overtime. It includes questions regarding the time and place of the test, repeating lists of words, arithmetic such as the serial sevens, language use and comprehension, and basic motor skills. MMSE score > = 25, 21-24,10-20 and < = 9 are indicator of normal cognition state, mild, moderate and severe cognitive impairment. [26] Statistical analysis Statistical analysis was performed using Statistical Package for the Social Sciences so ware (SPSS, version 18.0, SPSS Inc., Chicago, IL, USA) and descriptive and repeated measure of ANCOVA tests. P value <0.05 was considered statistically signifi cant.
RESULTS
In this study, 100 elderly patients with major depression were enrolled and 60 patients were randomly allocated in two intervention (n = 30) and placebo (n = 30) groups [ Figure 1 ]. Baseline characteristics of studied population in intervention and placebo groups are presented in [ Table 1 ]. Scores of severity of depression and quality of life, which were evaluated using GDS-15, HRSD and WHO-QOL-(brief) scales at baseline, 4 weeks and 8 weeks, a er initiation of trial are presented in [ Table 2 ]. According to these result, as shown in table 2, there was not a signifi cant diff erence between the results of the three scales and trends of changes throughout the study was not signifi cant either.
The side eff ects were recorded during the study. Reported side eff ects were mild and did not result in withdrawal. Frequency of side eff ects was not signifi cantly diff erent between two groups (P < 0.05) [ Table 3 ].
DISCUSSION
In this study, we investigate the eff ect of add-on memantine versus placebo to citalopram for depressive symptoms and quality of life in older adults receiving 20 mg of citalopram. The results showed that memantine had no superior eff ect on the mentioned factors than placebo. The role of memantine in improving cognitive impairment in elderly patients has been reported in many studies. [27] Considering the therapeutic eff ect of citalopram in depressive elderly patients, [28] the aim of current study was to determine the eff ect of memantine add-on therapy in depressed elderly patients without obvious cognitive impairment (MMSE >24). In current study, mean score of MMSE and the cognitive status of the studied depressed patients were similar in two studied groups, so the possible role of memantine as an add-on therapy on depressive symptoms of elderly patients was investigated.
Although, the role of glutamate and its related NMDA receptor antagonists in modulating mood disorders have recognized in several animal and human studies, [29] but results of diff erent clinical trials in this regard is confl icting and inconclusive.
Zarate et al., indicated that a single intravenous dose of ketamin, an N-methyl-D-aspartate antagonist, has a rapid antidepressant eff ect. [30] The antidepressant eff ects of ketamine as well as its effects on reducing delayed therapeutic eff ects of other antidepressant agents have reported in some studies also. [31, 32] In this study, we examined the eff ect of memantine add-on therapy in elderly patients with depression in a double-blind placebo-controlled study. Memantine is another N-methyl-D-aspartate antagonist with partial trapping property and lower side eff ects than ketamin, with trapping the block property. [33] In addition, comparing with other NMDA receptor antagonists such as ketamine, it is well-tolerated NMDA receptor antagonists without any psychotomimetic eff ects. [34] The results would be helpful in planning new management strategies for elderly people aff ected with MDD and evaluating the mediating role of memantine in reducing delayed therapeutic eff ects of citalopram.
Our results are consistent with the results of Zarate et al. They conducted the fi rst double-blind placebo-controlled study on the eff ectiveness of memantine among patients with major depression. They did not report any antidepressant eff ect for mematine among depressed patients. [17] In a recent study in the USA, Lenze and colleagues examined the effect of memantine on the depressive symptoms of older adults a er a disabling medical event. They showed that memantine has no signifi cant eff ect in this regard. [35] Whereas in another study in Utah, Ferguson et al. have demonstrated an early-onset effi cacy of memantine in patients with major depression. [18] In their study, which had been designed as open-label study, the effi cacy as well as safety of fl exible dose of memantine (i.e increasing titration of 20 mg/d memantine to 30 or 40 mg/day in nonresponsive patients) in 8 patients with MDD was evaluated. According to their fi ndings, all effi cacy measures were improved in studied patients within 1 week a er memantine therapy. Improved status peaked at week 8 and remained during 12-week study period. They did not report any signifi cant side eff ect regarding memantine and its diff erent dosage. They concluded that memantine is a safe and eff ective drug in patients with MDD and recommended to evaluate the effi cacy of memantine in this regard through a double-blind, placebo-controlled study.
Koukopoulos et al., have investigated the mood-stabilizing eff ect of memantine as augmenting agent in patients with treatment-resistant BMD. Their results indicated sustained mood-stabilizing eff ect of memantine. [19] Though the methods of mentioned studies were not similar regarding evaluation of depressive symptoms and memantine administration, factors which could infl uence on the fi ndings of our study are as follows; short duration of the trial, dose of memantine and long duration of its dose upward titration. We used approved dose of memantine, 20 mg/daily, for treatment of dementia, but it seems that higher dose of the drug with short upward titration period would be more eff ective in elderly patients. Other studies with similar result have recommended to test the higher dose, also. [35, 17] As justifi ed by Zarete et al., selected dose of memantine in our study is suffi cient for evaluating the validity of the concept of using memantine for depression treatment in elderly.
Another explanation for obtained negative results is that the diff erent mechanism of action of memantine than ketamin regarding its lower affi nity to NMDA receptor and faster open-channel blocking/unblocking kinetics. [33] The limitation of current study was that the patients were not followed up for long term period to determine the long term eff ect of memantine. In addition, though our studied sample size was larger than other studies in this fi eld, it seems that further studies with larger sample size could help us to obtain be er conclusive results.
In sum, the outcome of this pilot clinical trial did not support the antidepressant eff ect of add-on memantine in elderly patients with depression receiving citalopram. It is recommended to design further studies considering mentioned limitations of current study and the eff ect on memantine with other antidepressant agents.
